LABAs, or long-acting asthma drugs - Novartis AG's Foradil, GlaxoSmithKline's Serevent and Advair, and AstraZeneca's Symbicort have been found to increase asthma-related morbidity and mortality, says the FDA.
These drugs already carry a tough, "black box" warning stating they "may increase the risk of asthma-related death.
To be fair, the drugs have benefits such as improved lung function [K - not applicable after the patient has died].